Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.87 SEK | +2.09% | -6.23% | +5.20% |
Sales 2024 * | 65.08M 5.95M 497M | Sales 2025 * | 471M 43.08M 3.59B | Capitalization | 1.68B 154M 12.84B |
---|---|---|---|---|---|
Net income 2024 * | -291M -26.62M -2.22B | Net income 2025 * | 105M 9.6M 801M | EV / Sales 2024 * | 27.4 x |
Net Debt 2024 * | 103M 9.39M 783M | Net cash position 2025 * | 61.97M 5.67M 473M | EV / Sales 2025 * | 3.44 x |
P/E ratio 2024 * |
-6.05
x | P/E ratio 2025 * |
8.41
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.61% |
Latest transcript on Egetis Therapeutics AB
1 day | +2.09% | ||
1 week | -6.23% | ||
Current month | -12.13% | ||
1 month | -13.17% | ||
3 months | -3.29% | ||
6 months | +24.76% | ||
Current year | +5.20% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 16/17/16 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 31/17/31 |
Chief Tech/Sci/R&D Officer | - | 05/22/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
BRD | Director/Board Member | 59 | 01/21/01 |
Director/Board Member | 50 | 01/20/01 | |
Thomas Lönngren
CHM | Chairman | 73 | 01/21/01 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 5.87 | +2.09% | 213 753 |
26/24/26 | 5.75 | -3.20% | 568,552 |
25/24/25 | 5.94 | +0.17% | 152,280 |
24/24/24 | 5.93 | -5.57% | 271,959 |
23/24/23 | 6.28 | +0.32% | 137,986 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 08:59 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.20% | 153M | |
-2.45% | 103B | |
+1.86% | 95.28B | |
+1.46% | 22.15B | |
-15.78% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.30% | 16.05B | |
+4.86% | 13.68B | |
+35.42% | 12.17B |
- Stock Market
- Equities
- EGTX Stock